Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$105.70 USD

105.70
741,868

-0.75 (-0.71%)

Updated Nov 11, 2024 02:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Novartis (NVS) Beats on Q1 Earnings, Sandoz Posts Growth

by Zacks Equity Research

Novartis (NVS) beats on earnings in the first quarter but sales lag expectations. Generic Sandoz business returns to growth.

Novartis (NVS) Gets Positive CHMP Opinion on Lung Cancer Drug

by Zacks Equity Research

The CHMP gives a positive opinion on, and recommends approval for Novartis' (NVS) Tabrecta for treating patients with METex14 advanced non-small cell lung cancer.

KemPharm (KMPH) Starts Early-Stage Cardiovascular Safety Study

by Zacks Equity Research

KemPharm (KMPH) initiates dosing in a phase I study to evaluate the cardiovascular safety profile of its lead pipeline candidate, KP1077's sole active API, serdexmethylphenidate.

BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study

by Zacks Equity Research

BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.

    BeiGene (BGNE) Brukinsa Superior to Imbruvica in Leukemia Study

    by Zacks Equity Research

    BeiGene (BGNE) is comparing Brukinsa to AbbVie's Imbruvica as a treatment for R/R CLL or SLL. Brukinsa achieves superior ORR versus Imbruvica in a phase III study.

    Kinjel Shah headshot

    Pharma Stock Roundup: PFE to Buy RSV Drugmaker, FDA Updates for NVS, MRK and RHHBY

    by Kinjel Shah

    Pfizer (PFE) announces plans to acquire ReViral for up to $525 million. Merck (MRK), Novartis (NVS) and Roche (RHHBY) provide FDA updates.

    Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in Kids

    by Zacks Equity Research

    Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.

    Novartis (NVS) Anti-PD-1 Drug Validated by EMA for Lung Cancer

    by Zacks Equity Research

    Novartis (NVS) application seeking approval of tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indications gets EMA's validation.

    Novartis (NVS) Gets FDA Nod for Vijoice in Rare Disorder

    by Zacks Equity Research

    The FDA approves Novartis' (NVS) Vijoice (alpelisib) for the treatment of select patients with PIK3CA-related overgrowth spectrum.

    Accenture (ACN) Joins Health Data Collaborative, AI4BetterHearts

    by Zacks Equity Research

    Accenture's (ACN) goal behind joining the collaborative is to support and advance cardiovascular disease prevention through integrating innovation and emerging technologies.

    Kinjel Shah headshot

    Pharma Stock Roundup: FDA Nod for 2nd COVID Booster, New Approvals for AZN, GSK, NVS

    by Kinjel Shah

    FDA authorizes second booster dose of PFE and MRNA COVID-19 vaccines for older adults. RHHBY's late-stage study for ES-SCLC fails.

    Novartis (NVS) Beovu Gets Label Expansion for DME in EU

    by Zacks Equity Research

    Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.

    The Zacks Analyst Blog Highlights Visa, Novartis, Deere & Company, Airbnb, and Edwards Lifesciences

    by Zacks Equity Research

    Visa, Novartis, Deere & Company, Airbnb, and Edwards Lifesciences have been included in this Analyst Blog.

    Sheraz Mian headshot

    Top Stock Reports for Visa, Novartis & Deere

    by Sheraz Mian

    Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Novartis AG (NVS), and Deere & Company (DE).

    Novartis (NVS) Gets Positive CHMP Opinion for Jakafi, Kymriah

    by Zacks Equity Research

    Novartis (NVS) obtains positive CHMP opinion for the label expansion of Jakafi and Kymriah.

    The Zacks Analyst Blog Highlights Novartis, Merck and Pfizer

    by Zacks Equity Research

    Novartis, Merck and Pfizer have been included in this Analyst Blog.

    Novartis' (NVS) Pluvicto Gets FDA Nod for Advanced Prostate Cancer

    by Zacks Equity Research

    The FDA okays Novartis' (NVS) targeted radioligand therapy Pluvicto to treat PSMA-positive metastatic castration-resistant prostate cancer.

    Kinjel Shah headshot

    Pharma Stock Roundup: NVS, MRK Get FDA Nod, PFE Ulcerative Colitis Study Succeeds

    by Kinjel Shah

    FDA approves Novartis' (NVS) Pluvicto for a certain type of advanced prostate cancer and Merck's (MRK) Keytruda for expanded use in endometrial carcinoma. Pfizer's (PFE) late-stage ulcerative colitis study on etrasimod meets goal.

    Incyte's (INCY) Going Gets Tough Due to Pipeline Setbacks

    by Zacks Equity Research

    The recent pipeline setbacks will weigh on Incyte's (INCY) growth trajectory and jeopardize its plans to diversify its revenue base.

    Incyte (INCY) Label Expansion for Ruxolitinib Cream Delayed

    by Zacks Equity Research

    Incyte' s (INCY) sNDA seeking label expansion of ruxolitinib cream gets extended by three months by the FDA for reviewing additional information.

    Novartis (NVS) Announces Data on Zolgensma, Acquires Coalesce

    by Zacks Equity Research

    Novartis (NVS) reports positive data on SMA treatment from a phase III study. It also acquires Coalesce Product Development Limited to strengthen its respiratory and complex generics business.

    Voyager (VYGR) Gains on Deal With Novartis for Gene Therapies

    by Zacks Equity Research

    Voyager (VYGR) stock rises on the license option agreement with Novartis to get a target-specific access to next-generation TRACER AAV capsids for gene therapy programs.

    The Zacks Analyst Blog Highlights NVIDIA, Novartis AG, NextEra Energy, The Goldman Sachs Group and Amgen

    by Zacks Equity Research

    NVIDIA, Novartis AG, NextEra Energy, The Goldman Sachs Group and Amgen are included in this blog.

    Mark Vickery headshot

    Top Stock Reports for NVIDIA, Novartis & NextEra Energy

    by Mark Vickery

    Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Novartis AG (NVS), and NextEra Energy, Inc. (NEE).

    Should Value Investors Consider Novartis (NVS) Stock Now?

    by Zacks Equity Research

    Let's see if Novartis (NVS) stock is a good choice for value-oriented investors right now from multiple angles.